Value of urinary albumin-to-creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals

Diabetes Care

Volumn 31, Issue 12, 2008, Pages 2344-2348

  Friedman, Allon ^a   Marrero, David ^a,h   Ma, Yong ^b   Ackermann, Ronald ^a   Narayan, K M Venkat ^c   Barrett Connor, Elizabeth ^d   Watson, Karol ^e   Knowler, William C ^f   Horton, Edward S ^g  

^a INDIANA UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g JOSLIN DIABETES CENTER   (United States)

^h Diabetes Prevention Program Coordinating Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METFORMIN; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIABETES CONTROL; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIET RESTRICTION; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

ADULT; ALBUMINS; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDIABETIC STATE;

EID: 64349092368     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0148     Document Type: Article

References (22)

1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
2. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
3. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S, Hope Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondia- betic individuals. JAMA 286:421-426, 2001
4. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
5. Brantsma AH, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT: Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol 17:331-335, 2006
6. Forman JP, Brenner BM: 'Hypertension' and 'microalbuminuria': the bell tolls for thee. Kidney Int 69:22-28, 2006
7. Mykkänen L, Zaccaro DJ, O'Leary DH, Howard G, Robbins DC, Haffner SM: Mi- croalbuminuria and carotid artery intima- media thickness in nondiabetic and NIDDM subjects: the Insulin Resistance Atherosclerosis Study (IRAS). Stroke 28: 1710-1716, 1997
8. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM: Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 47:793-800, 1998
9. Palaniappan L, Carnethon M, Fortmann SP: Association between microalbumin- uria and the metabolic syndrome: NHANES III. Am J Hypertens 16:952958, 2003
10. Mykkanen L, Haffner SM, Kuusisto J, Pyorala K, Laakso M: Microalbuminuria precedes the development of NIDDM. Diabetes 43:552-557, 1994
11. Lee ET, Welty TK, Cowan LD, Wang W, Rhoades DA, Devereux R, Go O, Fabsitz R, Howard BV: Incidence of diabetes in American Indians of three geographic areas: the Strong Heart Study. Diabetes Care 25:49-54, 2002
12. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT, PREVEND Study Group. Urinary albumin excretion and its relation with C-re-active protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 28:2525-2530, 2005
13. YusufS, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
14. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luoman- maki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611-616, 1999
15. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Hol- man RR, Dream Trial Investigators: Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551-1562, 2006
16. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623-634, 1999
17. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHOconsultation. Diabet Med 15:539-553, 1998
18. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 23:1619-1629, 2000
19. Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H: Glucose tolerance and insulin release, a mathematical approach I. Assay of the (β-cell response after oral glucose loading. Diabetes 25:241-244, 1976
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Ho- meostasis model assessment: insulin resistance and (β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
21. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
22. Duncan ER, Walker SJ, Ezzat VA, Wheat- croft SB, Li JM, Shah AM, Kearney MT: Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. Am J Physiol Endocrinol Metab 293:E1311- E1319, 2007